ACIU Key Statistics, Chart & Performance
The current stock price of ACIU is 2.77 USD. In the past month the price decreased by -12.89%. In the past year, price decreased by -12.06%.
ACIU Latest News, Press Relases and Analysis
ACIU Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.74 | 396.55B | ||
| AMGN | AMGEN INC | 15.47 | 182.20B | ||
| GILD | GILEAD SCIENCES INC | 15.13 | 153.73B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.95 | 109.90B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.49 | 77.98B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 911.63 | 61.42B | ||
| INSM | INSMED INC | N/A | 44.06B | ||
| NTRA | NATERA INC | N/A | 32.66B | ||
| BIIB | BIOGEN INC | 10.76 | 26.43B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.97 | 20.42B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B |
Related stock screener links
About ACIU
Company Profile
AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud and currently employs 133 full-time employees. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
Company Info
AC IMMUNE SA
EPFL Innovation Park, Building B
Lausanne VAUD 1015 CH
CEO: Andrea Pfeifer
Employees: 133
Phone: 41213459121
AC IMMUNE SA / ACIU FAQ
Can you describe the business of AC IMMUNE SA?
AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud and currently employs 133 full-time employees. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
What is the current price of ACIU stock?
The current stock price of ACIU is 2.77 USD. The price increased by 1.09% in the last trading session.
Does AC IMMUNE SA pay dividends?
ACIU does not pay a dividend.
What is the ChartMill rating of AC IMMUNE SA stock?
ACIU has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Should I buy ACIU stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ACIU.
What is the employee count for ACIU stock?
AC IMMUNE SA (ACIU) currently has 133 employees.
Can you provide the market cap for AC IMMUNE SA?
AC IMMUNE SA (ACIU) has a market capitalization of 278.14M USD. This makes ACIU a Micro Cap stock.
ACIU Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to ACIU. When comparing the yearly performance of all stocks, ACIU turns out to be only a medium performer in the overall market: it outperformed 63.57% of all stocks.
ACIU Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ACIU. Both the profitability and financial health of ACIU have multiple concerns.
ACIU Financial Highlights
Over the last trailing twelve months ACIU reported a non-GAAP Earnings per Share(EPS) of -0.9. The EPS decreased by -75.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -41.88% | ||
| ROE | -115.1% | ||
| Debt/Equity | 0.06 |
ACIU Forecast & Estimates
9 analysts have analysed ACIU and the average price target is 9.18 USD. This implies a price increase of 231.41% is expected in the next year compared to the current price of 2.77.
For the next year, analysts expect an EPS growth of -49.91% and a revenue growth -85.17% for ACIU